GT Biopharma Analyst Ratings
GT Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/07/2023 | 614.29% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 06/05/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/17/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/16/2023 | 614.29% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 04/03/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 03/31/2023 | 614.29% | EF Hutton | → $2 | Reiterates | → Hold |
| 01/05/2023 | 614.29% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 1685.71% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 8828.57% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 7400% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 8828.57% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/08/08 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 08/07/2023 | 614.29% | EF Hutton | →$2 | 重申 | 保持→保持 |
| 06/05/2023 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 2023年05月17日 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 2023年05月16日 | 614.29% | EF Hutton | →$2 | 重申 | 保持→保持 |
| 04/03/2023 | 1685.71% | HC Wainwright公司 | →$5 | 重申 | →購買 |
| 03/31/2023 | 614.29% | EF Hutton | →$2 | 重申 | →保留 |
| 01/05/2023 | 614.29% | EF Hutton | →$2 | 開始承保 | →保留 |
| 09/13/2022 | 1685.71% | HC Wainwright公司 | $25→$5 | 維護 | 買 |
| 2021/05/24 | 8828.57% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
| 04/13/2021 | 7400% | B.萊利證券 | →$21 | 開始承保 | →購買 |
| 03/17/2021 | 8828.57% | 羅斯資本 | →$25 | 開始承保 | →購買 |
What is the target price for GT Biopharma (GTBP)?
GT Biophma(GTBP)的目標價格是多少？
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $5.00 expecting GTBP to rise to within 12 months (a possible 1685.71% upside). 9 analyst firms have reported ratings in the last year.
GT Biophma(納斯達克代碼：GTBP)的最新目標價是由HC Wainwright&Co.於2023年8月8日報道的。這家分析公司將目標價定為5美元，預計英鎊將在12個月內上漲至(可能上漲1685.71%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for GT Biopharma (GTBP)?
GT Biophma(GTBP)的最新分析師評級是什麼？
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by HC Wainwright & Co., and GT Biopharma reiterated their buy rating.
GT Biophma(納斯達克代碼：GTBP)的最新分析師評級由HC Wainwright&Co.提供，GT Biophma重申其買入評級。
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
GT Biophma(GTBP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與GT Biophma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。GT Biophma的最後一次評級是在2023年8月8日提交的，所以你應該預計下一次評級將在2024年8月8日左右的某個時候提供。
Is the Analyst Rating GT Biopharma (GTBP) correct?
分析師對GT Biophma(GTBP)的評級正確嗎？
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a reiterated with a price target of $0.00 to $5.00. The current price GT Biopharma (GTBP) is trading at is $0.28, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但GT Biophma(GTBP)的最新評級被重申，目標價在0.00美元至5.00美元之間。GT Biophma(GTBP)目前的交易價格為0.28美元，在分析師的預測範圍內。